For example, the expression of CAF markers, including α-SMA, FSP1, and FAP, is associated with the clinical outcome of a cohort of 289 CRC patients, and surprisingly, the combination of these CAF markers with M2 macrophage markers, CD163 and DCSIGN, identifies significant differences in the survival of advanced-stage patients, demonstrating a prognostic involvement of interrelationships between markers of CAFs and M2 macrophages in CRC patient survival (Herrera et al., 2013a). The gene discussed is CD209; the disease is colorectal carcinoma.